LGALS3BP
Galectin-3-binding protein
Protein Summary
Promotes integrin-mediated cell adhesion. May stimulate host defense against viruses and tumor cells. The galectins are a family of beta-galactoside-binding proteins implicated in modulating cell-cell and cell-matrix interactions. LGALS3BP has been found elevated in the serum of patients with cancer and in those infected by the human immunodeficiency virus (HIV). It appears to be implicated in immune response associated with natural killer (NK) and lymphokine-activated killer (LAK) cell cytotoxicity. Using fluorescence in situ hybridization the full length 90K cDNA has been localized to chromosome 17q25. The native protein binds specifically to a human macrophage-associated lectin known as Mac-2 and also binds galectin 1. [provided by RefSeq, Jul 2008]
- ENST00000262776
- ENSP00000262776
- ENSG00000108679
- M2BP
- 90K
- M2BP
- gp90
- CyCAP
- BTBD17B
- MAC-2-BP
- TANGO10B
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
virus perturbation | 1 | ||
interacting protein | 0.99 | ||
gene perturbation | 0.96 | ||
disease perturbation | 0.93 | ||
small molecule perturbation | 0.85 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 507.14 (req: < 5)
Gene RIFs: 112 (req: <= 3)
Antibodies: 359 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 507.14 (req: >= 5)
Gene RIFs: 112 (req: > 3)
Antibodies: 359 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 5
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0